PARP1 and non-small cell lung carcinoma: Beyond the well-established synthetic lethality of PARPi in HR-deficient cells, emerging evidence suggests that PARP inhibition may also exert therapeutic effects in HR-proficient NSCLC (Jiang et al., 2019; Oza et al., 2015).